FOXO1 and primary effusion lymphoma: Although we have identified FoxO1 and FoxO3 as promising therapeutic targets and AS1842856 as a therapeutic reagent for PEL, we have only examined their effects on BJAB-KSHV and three PEL cell lines so far.